Comparative Pharmacology
Head-to-head clinical analysis: DEPO MEDROL versus FLORONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPO MEDROL versus FLORONE.
DEPO-MEDROL vs FLORONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylprednisolone acetate is a synthetic glucocorticoid receptor agonist that modulates gene expression to suppress inflammation, immune responses, and adrenal function by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
Glucocorticoid receptor agonist; induces phospholipase A2 inhibitory proteins (lipocortins), which suppress release of arachidonic acid and subsequent prostaglandin/leukotriene synthesis; also suppresses cytokine production and immune cell migration.
IV: 10-40 mg every 1-2 weeks; IM: 40-120 mg every 1-4 weeks; Intra-articular/soft tissue: 4-80 mg per injection, repeat every 1-5 weeks as needed.
Topical: Apply a thin layer to affected skin once or twice daily. Maximum use: 45 g/week.
None Documented
None Documented
Plasma terminal elimination half-life: 2.5-4.0 hours (methylprednisolone acetate formulation). Duration of adrenal suppression correlates with tissue esterase hydrolysis and prolonged tissue retention.
Terminal elimination half-life of approximately 2-3 hours; clinical context: duration of action may extend beyond half-life due to tissue binding.
Primarily hepatic metabolism; renal excretion of metabolites (<10% unchanged). Fecal excretion is minor (<5%).
Renal (approximately 80% as metabolites, <5% unchanged), biliary/fecal (remainder).
Category C
Category C
Corticosteroid
Corticosteroid